Search research articles
Contact Us
Filters
Showing results (431-440 of 468) with videos related to
Page
of 47
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Nature Medicine
|
December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
ESMO Open
|
July 13, 2024
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
C Fong, B Patel, C Peckitt, et al.
Advances in Genomics and Genetics
|
April 30, 2019
Frequency of frontotemporal dementia gene variants in <i>C9ORF72</i>, <i>MAPT</i>, and <i>GRN</i> in academic versus commercial laboratory cohorts
Natasha Zr Steele, Alison R Bright, Suzee E Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Acta Neuropathologica
|
August 23, 2017
Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia
Nicholas T Olney, Carolina Alquezar, Eliana Marisa Ramos, et al.
Page
of 47
Search research articles
Search
Showing results (431-440 of 468) with videos related to
Sort By:
Page
of 47
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Nature Medicine
|
December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
ESMO Open
|
July 13, 2024
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
C Fong, B Patel, C Peckitt, et al.
Advances in Genomics and Genetics
|
April 30, 2019
Frequency of frontotemporal dementia gene variants in <i>C9ORF72</i>, <i>MAPT</i>, and <i>GRN</i> in academic versus commercial laboratory cohorts
Natasha Zr Steele, Alison R Bright, Suzee E Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Acta Neuropathologica
|
August 23, 2017
Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia
Nicholas T Olney, Carolina Alquezar, Eliana Marisa Ramos, et al.
Page
of 47